Table 3.
Cancer type | Body fluid | Biomarker | Method/technique | Clinical significance | Reference |
---|---|---|---|---|---|
Breast cancer | Plasma serum | Integrins | ELISA | Src activation and upregulation of proinflammatory S100 genes | [100] |
miR-9 | qRT-PCR | ||||
HER2, CD47, Del-1, miR-1246, miR-21 | Microfluidic chip Adaptive dynamic artificial polyligand targeting (ADAPT) |
Upregulated, miR-1246 attacks CCNG2 and promotes drug resistance against cancer | [192] | ||
Glutathione S-transferase P1 (GSTP1), ubiquitin carboxyl terminal hydrolase-1 (UCH-L1), NANOG, NEUROD1, HER2, KDR, CD49d, CXCR4, CD44, miR-340-5p, miR-130a-3p, miR-93-5p, miR-17-5p | qRT-PCR FCM PCR array |
Partial remission (PR)/complete remission (CR) Progression-free survival (PFS) Disease-free survival (DFS) Distant organ metastasis Recurrence |
[193] | ||
TRPC5 | Confocal analysis, Western blot | Elevated levels show poor prognosis | [194] | ||
Survivin | ELISA | Elevated survivin-ΔEx3 splice variant, while differential expression of survivin-2B in BC patients | [195] | ||
Periostin | Nanoparticle tracking analysis | Higher levels in patients with lymph node metastasis | [196] | ||
miR-373 | qRT-PCR | Controversial effect on BC | [197] | ||
| |||||
Glioblastoma | Cerebrospinal fluid (CSF) Serum |
EGFRvIII | Western blot | Mutated EGFRvIII cause: increase mitogenic factor Akt, suppress apoptosis, downregulate Bcl-2 | [198] |
PTRF/caveolin-1, miR-21 | qRT-PCR | Elevation leads to recurrence | [181] | ||
DNM3, p65, p53 | Microarray | Elevated levels in primary and recurrent GBC | [199] | ||
| |||||
Melanoma | Serum Plasma |
MDA-9, GRP78 | Western blot | Elevation in metastasis | [200] |
miR-125b | Western blot | Melanoma patient PDS and OS patients showed high survival | [201] | ||
PD-1, CD28 | qRT-PCR | Downregulation leads to MM progression | [202] | ||
MIA, S-100 | Immunoaffinity capture | Interaction with ECM proteins: promote metastasis | [203] | ||
CD63, caveolin-1 | In-house sandwich ELISA (Exotest) | Elevated levels in MP | [204] | ||
| |||||
Hepatocellular carcinoma (HCC) | Serum | TAK1 | Microarray analysis | Upregulation | [205] |
miR-320a | qRT-PCR | Cancer suppression | [206] | ||
miR-122 | qRT-PCR | Upregulate septin-9: taxol resistance | [207] | ||
miR-21, 211, 222, 224 | qRT-PCR | Upregulation in cancer patients | [208] | ||
miR-718, 1246 | qRT-PCR | Downregulation causes HCC progression, miR-718 targets EGR-3 and increases proliferation | [209] | ||
| |||||
Ovarian cancer | Plasma Serum |
miR-21, 141, 200a, 200c, 200b, 203, 205, 214, 222-3p | miRNA array | Suppress apoptosis through binding to APAF1, grant paclitaxel resistance. miR-21 targets Bcl-2, TPM1, PDCD4, maspin, and PTEN leading to tumor proliferation. miR-200 attacks ZEB1/2 leading to EM. miR-205 targets the HER2 pathway causing tumor suppression | [210] |
Phosphatidylserine | Nanoparticle tracking analysis | Elevated levels in cancer patients | [211] | ||
Claudin-4 | Western blot | Upregulation in OC patients | [212] | ||
| |||||
Multiple myeloma | Serum | MSC-derived miR-15a, Let-7b, miR-18a | qRT-PCR array analysis | Suppressor of MM Elevated levels in cancer patients |
[213] |
| |||||
Colorectal cancer (CRC) | Serum | miR-9 | qRT-PCR | Inhibits suppressive expression SOCS5, upregulate endothelial cell migration | [214] |
CRNDE-h, miR-19a-3p, 21-5p, 425-5p, 17-92a | ExoScreen | Upregulation in cancer patients | [215] | ||
miR-4772-3p | qRT-PCR | Lower level causes cancer recurrence | [216] | ||
let-7a, miR150, 1246, 1229, 223, 21, 23a | qRT-PCR | let-7a binds KRAS and inhibits cancer, miR-21 downregulates p53 | [217] | ||
| |||||
Prostate cancer | Serum Urine Plasma |
LncRNA-p21, miR-21, 375 miR-1290 |
qRT-PCR | Elevation in prostate cancer patients | [218] |
PSA, PSMA, P-glycoprotein | qRT-PCR | Elevation causes castration-resident prostate cancer Elevation in docetaxel-resistant patients |
[219] | ||
miR-1246 | Western blot | Overexpression leads to positive metastasis | [220] | ||
TM256, LAMTOR1, VATL, ADIRF, survivin | qRT-PCR ELISA |
VATL increases metastasis, LAMTOR1 regulates mTOR signaling | [221] | ||
| |||||
Pancreatic cancer | Serum | Glypican-1 miR-1246, 4644, 3976, 4306 |
GFP qRT-PCR |
Increased levels in pancreatic cancer patient's upregulation in 83% of pancreatic cancer patients | [222] |
CD44, V6, Tspan8, EpCAM, CD104 | ELISA | CD44v6 target MET and VEFGR-2 pathways to promote metastasis | [223] | ||
| |||||
Non-small-cell lung cancer (NSCLC) | Plasma | miR-302c, 302a, 126 | Western blot | Elevation in cancer patients | [224] |
Bronchoalveolar lavage | EML4-ALK | Electron microscopy | |||
miR 181-5p, 30a-3p, 361-5p, 15b-5p, 320b, 30e-3p | Nanoparticle tracking analysis | ||||
EpCAM, NY-ESO-1, Alix, PLAP, miR-24 | miRNA-seq | EFGR mutation leads to metastasis, miR-24 targets Jab1/CSN5 to promote tumorigenesis | [225] | ||
| |||||
Acute myeloid leukemia (AML) | Plasma | CD34 | Immunoaffinity capture | Elevated CD34+ exosomes in AML patients | [226] |
| |||||
Cervical cancer | Cervicovaginal lavage specimens | miR-21, 146a | qRT-PCR | Elevation in HPV+ patients | [227] |
Survivin | qRT-PCR | Suppress genotoxic-induced stress apoptosis and enhance proliferation | [228] | ||
| |||||
Bladder cancer | Serum Urine |
Lnc-UCA1 | qRT-PCR | Elevated expression in BC patients | [229] |
EDIL-3 | Western blot | Tumor progression via activation of EFGR | [230] |